GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+49.08%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$642M
AUM Growth
+$642M
(+9.4%)
Cap. Flow
-$71.6M
Cap. Flow
% of AUM
-11.17%
Top 10 Holdings %
Top 10 Hldgs %
51.56%
Holding
44
New
10
Increased
11
Reduced
8
Closed
9
Top Buys
| 1 |
Viridian Therapeutics
VRDN
|
$23.4M |
| 2 |
Esperion Therapeutics
ESPR
|
$21.4M |
| 3 |
MindMed
MNMD
|
$18.8M |
| 4 |
Dianthus Therapeutics
DNTH
|
$18.8M |
| 5 |
Outlook Therapeutics
OTLK
|
$17.7M |
Top Sells
| 1 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$102M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$31M |
| 3 |
RAPT Therapeutics
RAPT
|
$27.3M |
| 4 |
Alkermes
ALKS
|
$24.3M |
| 5 |
Vaxcyte
PCVX
|
$22.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurogene
NGNE
$264M
| $51.1M | 7.97% | 1,004,291 +10,062 | +1% | +$512K |
|
|
ALPN
2
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $44.7M | 6.97% | 1,128,499 -2,574,934 | -70% | -$102M |
|
3
UroGen Pharma
URGN
$900M
| $39.3M | 6.13% | 2,620,545 | – | – |
|
|
ABVX
4
Abivax
ABVX
$6.12B
| $35.6M | 5.55% | 2,488,483 +938,483 | +61% | +$13.4M |
|
5
Evolus
EOLS
$494M
| $34.3M | 5.35% | 2,450,000 +450,000 | +23% | +$6.3M |
|
6
Pliant Therapeutics
PLRX
$101M
| $27.6M | 4.3% | 1,851,864 +28,680 | +2% | +$427K |
|
7
Apogee Therapeutics
APGE
$2.17B
| $26.6M | 4.14% | 400,000 | – | – |
|
|
JBIO
8
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $26.2M | 4.09% | 887,690 -150,000 | -14% | -$4.44M |
|
|
9
Viridian Therapeutics
VRDN
$1.5B
| $23.4M | 3.64% | +1,335,000 | New | +$23.4M |
|
10
AnaptysBio
ANAB
$569M
| $22M | 3.43% | 976,981 | – | – |
|
|
11
Esperion Therapeutics
ESPR
$448M
| $21.4M | 3.34% | +8,000,000 | New | +$21.4M |
|
12
Insmed
INSM
$28.8B
| $21M | 3.28% | 775,585 +549,673 | +243% | +$14.9M |
|
13
Arcellx
ACLX
$3.85B
| $20.9M | 3.25% | 300,000 +251,736 | +522% | +$17.5M |
|
14
Xenon Pharmaceuticals
XENE
$2.98B
| $19.6M | 3.06% | 456,148 -143,852 | -24% | -$6.19M |
|
|
15
MindMed
MNMD
$676M
| $18.8M | 2.93% | +2,000,000 | New | +$18.8M |
|
|
16
Dianthus Therapeutics
DNTH
$759M
| $18.8M | 2.92% | +625,000 | New | +$18.8M |
|
|
17
Outlook Therapeutics
OTLK
$37.8M
| $17.7M | 2.75% | +1,480,000 | New | +$17.7M |
|
18
Amicus Therapeutics
FOLD
$2.34B
| $17.6M | 2.75% | 1,495,500 +215,000 | +17% | +$2.53M |
|
19
Ocular Therapeutix
OCUL
$2.12B
| $15.7M | 2.45% | 1,728,723 +1,028,723 | +147% | +$9.36M |
|
20
Dynavax Technologies
DVAX
$1.19B
| $15.7M | 2.45% | +1,264,920 | New | +$15.7M |
|
21
Cytokinetics
CYTK
$4.23B
| $14.2M | 2.21% | 202,202 -297,798 | -60% | -$20.9M |
|
|
OPTN
22
DELISTED
OptiNose
OPTN
| $12.8M | 2% | 8,786,318 -53,621 | -0.6% | -$78.3K |
|
23
Jasper Therapeutics
JSPR
$45.5M
| $12M | 1.86% | +407,550 | New | +$12M |
|
|
ITCI
24
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $10.4M | 1.62% | 150,000 +39,393 | +36% | +$2.73M |
|
25
Merus
MRUS
$4.98B
| $10.1M | 1.57% | 223,288 +203,288 | +1,016% | +$9.15M |
|